Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects of Vyvanse, an FDA approved medication
used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), on brain activity
in adults with attention-deficit hyperactivity disorder (ADHD). Participants may qualify for
participation in this study because they have ADHD and are willing to participate in two
Functional Magnetic Resonance Imaging (fMRI) scans and receive Vyvanse for treatment of their
symptoms. Another purpose of this study is to collect and bank samples of blood for research
to examine how genes influence brain activation seen during the brain scans. The study also
seeks to find out whether certain genes are related to ADHD. Participants' entire genetic
makeup will not be determined from this sample.